Johnson & Johnson

Yahoo Finance • 3 hours ago

Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether Johnson & Johnson is still fairly priced after its recent run, this article will help you weigh what... Full story

Yahoo Finance • 6 hours ago

These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.

As technology, financial and consumer discretionary sectors struggle this year, investors have shifted to an odd mix of economically sensitive sectors such as materials and energy along with consumer staples and utilities. Continue Reading... Full story

Yahoo Finance • yesterday

Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Philadelphia jury orders Johnson & Johnson to pay damages in a talc related ovarian cancer case, the first plaintiff win there sin... Full story

Yahoo Finance • yesterday

Jim Cramer on Caterpillar: “We Like Their Stuff”

Caterpillar Inc. (NYSE:CAT) is one of the stocks Jim Cramer commented on. Cramer mentioned the stock during the episode and commented: What else do we need so badly that we’ll pay anything for? Well, how about Caterpillar? We like their s... Full story

Yahoo Finance • yesterday

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate... Full story

Yahoo Finance • 2 days ago

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expe... Full story

Yahoo Finance • 2 days ago

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day... Full story

Yahoo Finance • 3 days ago

Noteworthy ETF Outflows: SPY, XOM, JNJ, MU

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $3.8 billion dollar o... Full story

Yahoo Finance • 3 days ago

ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock

On Feb. 4, 2026, ACR Alpine Capital Research, LLC disclosed a significant buy of Arrow Electronics(NYSE:ARW) in the fourth quarter. What happened According to a filing with the Securities and Exchange Commission dated Feb. 4, 2026, ACR A... Full story

Yahoo Finance • 3 days ago

RNA-Based Therapeutics & Vaccines Market is projected to reach USD 2.32 Billion by 2032, growing at a CAGR of 5.50% during 2025–2032, Driven by the Rapid Expansion of mRNA Platform Applications: AnalystView Market Insights

San Francisco, USA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The RNA-based Therapeutics and Vaccines Market was valued at USD 1,285.10 million in 2024 and is projected to reach approximately USD 2,320.54 million by 2032, expanding at a CAGR of... Full story

Yahoo Finance • 3 days ago

RYBREVANT®▼ (amivantamab) par voie sous-cutanée, approuvé par la Commission Européenne pour une administration toutes les trois ou quatre semaines chez les patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR

L’amivantamab sous-cutané (SC) réduit l’administration de plusieurs heures à quelques minutes, avec une efficacité et une sécurité comparables à celles de l’amivantamab intraveineux (IV)1,2,3,4,5 L’amivantamab SC est désormais autorisé po... Full story

Yahoo Finance • 3 days ago

Subkutanes RYBREVANT®▼ (amivantamab) von der Europäischen Kommission für die dreiwöchentliche und vierwöchentliche Verabreichung bei Patienten mit fortgeschrittenem EGFR-mutiertem nicht-kleinzelligem Lungenkrebs zugelassen

Subkutanes RYBREVANT®▼ (amivantamab) von der Europäischen Kommission für die dreiwöchentliche und vierwöchentliche Verabreichung bei Patienten mit fortgeschrittenem EGFR-mutiertem nicht-kleinzelligem Lungenkrebs zugelassen Mit subkutanem... Full story

Yahoo Finance • 3 days ago

How Shifting Analyst Targets Are Rewriting The Johnson & Johnson (JNJ) Investment Story

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Johnson & Johnson’s fair value estimate has been adjusted from US$231.25 to US$232.50, a move of about 0.5% that fine tunes the pr... Full story

Yahoo Finance • 3 days ago

Johnson & Johnson Enterprise Technology Analysis Report 2025: Accelerators, Digital Strategies, Innovation Programs, Incubators, Technology Initiatives, Partnerships, Investment & Acquisition

Company Logo Johnson & Johnson's market opportunities lie in its innovative medicines across key therapy areas and advanced medical devices. Its focus on digital transformation, tech partnerships, and strategic innovations highlights pote... Full story

Yahoo Finance • 3 days ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic... Full story

Yahoo Finance • 3 days ago

Global Cosmetics Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo The Global Cosmetics Market is set for significant growth, projected to leap from US$ 346.1 billion in 2025 to US$ 526.74 billion by 2033, with a CAGR of 5.39%. This growth is driven by soaring demand for vegan cosmetics, pro... Full story

Yahoo Finance • 3 days ago

OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye s... Full story

Yahoo Finance • 4 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Blue Hat Interac.Entert.Techn. 199,973,207 0.0781 0.066 0.071 +0.0052 Re... Full story

Yahoo Finance • 4 days ago

What Johnson & Johnson (JNJ)'s Prostate Cancer Drug Lawsuit Means For Shareholders

In February 2026, Bayer filed a lawsuit in U.S. federal court accusing Johnson & Johnson and Janssen Biotech of falsely promoting the superiority of prostate cancer drug ERLEADA over Bayer’s NUBEQA using what Bayer claims is a flawed real‑... Full story

Yahoo Finance • 4 days ago

Vision Care Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo The Vision Care market is expected to grow from US$81.23 billion in 2025 to US$117.75 billion by 2033, at a CAGR of 4.75%. Factors driving this growth include enhanced access to healthcare, increased awareness of eye health,... Full story